Agenus Inc., (Agenus) is a known biotechnology company that concentrates on developing and commercializing technologies for the treatment of cancers and infectious diseases. The Company was previously known as Antigenics Inc. and uses immunological approaches for its products.
The Company’s products and technologies include the following:
- Heat Shock Protein Technology
- The Prophage Series of Cancer Vaccines
- Phase 3 Renal Cell Carcinoma Program
Its key assets involve the:
- Prophage Series of cancer vaccines
- QS-21 Stimulon adjuvant (QS-21)
This Prophage series of cancer vaccines are based on its core heat shock protein technology. Meanwhile, the QS-21 is an adjuvant and is used as a substance that is added up to any vaccines or immunotherapy that will enhance immune response. Lastly, the HerpV is a therapeutic vaccine for the treatment of genital herpes, which is based on the Company’s Heat shock proteins (HSP) technology.
Heat Shock Protein Technology
This is known as stress proteins wherein the expression is increased when cells experience various stresses like extremes of temperature (hot or cold) and oxygen deprivation.
The Prophage Series of Cancer Vaccines
This is basically the primary product under the Company’s portfolio of patient-specific HSP-based therapeutic cancer vaccines which involves the following:
- R-Series candidates in renal cell carcinoma (RCC)
- M-Series candidates in melanoma
- G-Series candidates in glioma
- NP-Series candidate in pediatric neurological tumors
Phase 3 Renal Cell Carcinoma Program
The Company started a Phase 3, multicenter, international trial for non-metastatic RCC for the treatment of renal cell carcinoma.
This is cancer that affects the central nervous system and begins in the glial cells (connective tissue cells that surround and support nerve cells). This is a fatal disease. The Company has already started a Phase 2 clinical trial with Prophage Series G-200 in recurrent, high-grade glioma is ongoing. This is led by the Brain Tumor Research Center at the University of California, San Francisco (UCSF).
Other Clinical Trials
The Company started the initial clinical trials of Prophage Series vaccines. These are focused on assessing feasibility, safety and preliminary efficacy; select studies measured immune response. Moreover, it also commenced a series of small, single-arm trials were performed in a range of solid tumor types.
Agenus Inc. (NASDAQ: AGEN) 52 week: 1.92 – 7.41 Mkt cap: 141.03M Shares: 22.49M